Fresenius NaturaLyte, GranuFlo Dialysis Heart Attack Lawsuit Allegations Update: FDA Cites Dialysis Center over Deficiencies as Much more Situations Filed

San Diego, CA (PRWEB) June 27, 2013

http://www.resource4thepeople.com/defectivemedicaldevices/Dialysis-Lawsuit.html

&#13

Resource4thePeople reports nowadays on its most current update to shoppers who are following the litigation involving allegations that Fresenius NaturaLyte and GranuFlo kidney dialysis products brought on life-threatening troubles for individuals.

&#13

The most current news is that as a federal judge moves forward on consolidated federal lawsuits* involving these allegations a search of U.S. Food and Drug Administration records shows that Fresenius was cited** by federal regulators more than deficiencies uncovered at 1 of the companys facilities.

&#13

In a warning letter dated March 13, 2013, FDA officials informed Fresenius Health-related Care officials that dialyzers manufactured at the companys Ogden, Utah plant are not in conformity with existing federal good manufacturing requirements.

&#13

The FDAs warning letter additional calls into query the good quality of goods that Fresenius is producing for kidney individuals and comes at a time when the federal court method has consolidated situations from across the nation containing allegations that GranuFlo and NaturaLyte allegedly have life-threatening side effects, stated Resource4thePeople.

&#13

We will continue to supply updates for shoppers who may possibly have been impacted by these dialysis goods and will report on the progress of the federal consolidated litigation. We also will continue to offer buyers free consultations about legal rights to which they may be entitled to seek compensation.

&#13

At least 161 federal NaturaLyte and GranuFlo lawsuits alleging severe heart difficulties and deaths from the use of these merchandise have been consolidated ahead of U.S. District Court Judge Douglas P. Woodlock, according to the court docket.*

&#13

The court filings also summarize the particular allegations involved that plaintiffs who used NaturaLyte and GranuFlo claim they must be compensated for:

&#13

These actions share factual troubles arising from allegations that Plaintiffs suffered injury or death brought on by the use of GranuFlo and/or NaturaLyte products in the course of hemodialysis, which allegedly might cause metabolic alkalosis in sufferers resulting in low blood stress, hypokalemia, hypoxemia, hypercapnia, cardiac arrhythmia, or cardiopulmonary arrest.

&#13

All the actions involve factual concerns relating to whether or not GranuFlo and NaturaLyte were defectively developed or manufactured, no matter whether Fresenius, the manufacturer of these dialysate goods, knew or ought to have known of the alleged propensity of these merchandise to result in injury and whether or not it supplied adequate directions and warnings with these goods.

&#13

Resource4thePeople, in response to inquiries from consumers, is informing them that even although this multidistrict litigation has been produced new inquiries will nevertheless be accepted and further circumstances will continue to be filed.

&#13

Amongst numerous new situations that have been not too long ago filed are those by:&#13

&#13

Baron and Budd Law Firm Tackles Fresenius GranuFlo Lawsuit


Dallas, TX (PRWEB) June 28, 2013

A MDL Statistics Report issued on May possibly 14th by the U.S. Judicial Panel on Multidistrict Litigation (JPML) claims that at least 161 Fresenius GranuFlo lawsuit situations have been filed in federal litigation in the district of Massachusetts considering that March. (IN RE: FRESENIUS GRANUFLO/NATURALYTE DIALYSATE LITIGATION, MDL NO. 2428)

&#13

People who have allegedly suffered severe injuries including cardiac arrest and heart attacks from these merchandise continue to speak to us, said Russell Budd, founder and managing shareholder of Baron and Budd, a national plaintiffs law firm handling GranuFlo lawsuit cases. At this time we have begun offering free GranuFlo lawsuit evaluations to these dialysis sufferers and their loved ones. As GranuFlo was a extensively employed dialysis product, we expect the quantity of GranuFlo lawsuit instances to continue to improve.

&#13

Both GranuFlo and NaturaLyte have been discussed in an Urgent Solution Notification sent by the dialysis drugs manufacturer Fresenius Healthcare Care to its client clinics in March of 2012 that pointed out achievable heart dangers linked with GranuFlo and NaturaLyte use. The U.S. Food and Drug Administration (FDA) took notice of the notification a number of months later and issued a Class 1 GranuFlo recall, a classification that is only issued when a healthcare item has a significant threat of serious injury or death. (http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm FDA, March 29, 2013)

&#13

According to court documents, GranuFlo lawsuit litigation was established by an order of the JPMB on March 29th. At the time, 11 Fresenius GranuFlo lawsuit instances had been transferred to the proceeding. In these GranuFlo lawsuit cases, plaintiffs allege that Fresenius Health-related Care was conscious of the significant heart risks linked with their goods, GranuFlo and NaturaLyte, and failed to sufficiently warn sufferers and doctors relating to the complete scope of the dangers.

&#13

In compliance with GranuFlo lawsuit litigation, dialysis sufferers who allegedly suffered critical heart injuries from GranuFlo and NaturaLyte use, like sudden heart attacks and sudden cardiac death, within 48 hours of dialysis therapy might have the opportunity to file a GranuFlo lawsuit against manufacturer Fresenius to receive compensation for lost wages, pain and suffering and healthcare costs. To find out much more about the GranuFlo lawsuit pay a visit to Baron and Budds site http://baronandbudd.com/regions-of-practice/pharmaceuticals/granuflo-lawyer/ or call Baron and Budds Chief GranuFlo lawyer at 1.866.844.4556.

&#13

If you or an individual you know has undergone dialysis treatments employing the GranuFlo or NaturaLyte dialysis drug and suffered severe overall health injuries, speak to Baron and Budds chief GranuFlo lawyer nowadays at 1.866.855.4556 or e-mail our chief GranuFlo lawyer at information (at) baronbudd (dot) com.

&#13

Baron and Budd has a effectively-established record of good results safeguarding the rights of individuals against large, negligent corporations, such as pharmaceutical organizations, for over 35 years. Recently, Baron and Budd lawyers were involved in litigation surrounding the diabetes drug Avandia. Baron and Budd represented more than 7,000 patients allegedly harmed by Avandia use, and presently represents numerous states in lawsuits against the manufacturer GlaxoSmithKline (In Re: Avandia Marketing and advertising, Sales Practices and Products Liability Litigation, MDL No. 1871, E.D. Pa.). In the 1990s, Baron and Budd was closely involved in litigation surrounding the then-common diet plan drug Fen-Phen. The resulting settlement was valued at over $ 1.275 billion (In re Diet regime Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Goods Liability Litigation, Case No. 98- MDL No. 1203 (E.D. Pa.).

&#13

About Baron &amp Budd

&#13

With offices in Dallas, Baton Rouge, Austin and Los Angeles, the law firm Baron Budd is nationally recognized with over 35 years of Protecting Whats Right for individuals, communities and firms harmed by negligence. Baron &amp Budds size and sources allow the firm to take on massive and complex circumstances. The firm represents individuals, governmental and enterprise entities in locations as diverse as water contamination, Gulf oil spill, Qui Tam, California Proposition 65 violations, unsafe drugs and health-related devices, Chinese drywall, deceptive marketing, consumer economic fraud, securities fraud and asbestos cancers such as mesothelioma.

&#13
&#13
&#13
&#13
&#13

A lot more Administrator Press Releases

GranuFlo Lawsuit Update: New Filings Highlight Alleged Hyperlink of GranuFlo to Cardiac Arrest, Reports Audet and Partners, LLP


San Francisco, CA (PRWEB) July 01, 2013

A new federal lawsuit filed in the United States District Court for the Southern District of Iowa (Case No. three:2013cv00073) alleges that the dialysis drug GranuFlo triggered the plaintiff to endure a heart attack shortly following dialysis therapy, causing a fatal collision.* This case has been added to federal multidistrict litigation No.2428 now pending before Judge Douglas P. Woodlock in Massachusetts, which lists 161 pending instances as component of this litigation.**

&#13

Numerous internal memoranda circulated inside Fresenius, the maker of GranuFlo, suggest that Fresenius might have identified of the heart attack threat associated with its merchandise use, even prior to an FDA recall.*** This enhanced danger is linked to elevated bicarbonate levels, a contributing factor in cardiac arrest.***

&#13

Since of the hazardous nature of GranuFlo, the FDA has issued a Class I recall of GranuFlo.**** In issuing the recall, the FDA warned buyers that the elevated sodium bicarbonate levels, could contribute to metabolic alkalosis, which is a substantial threat issue associated with low blood stress, hypokalemia, hypoxemia, hypercapnia and cardiac arrhythmia, which, if not appropriately treated, may culminate in cardiopulmonary arrest.**** The FDA concluded by stating that the serious adverse wellness consequences related with GranuFlo could even consist of death.****

&#13

Attorney William Audet, whose law firm Audet and Partners, LLP represents several plaintiffs in active lawsuits against Fresenius, is not surprised by the new lawsuit filings. “The complaints being added to the multidistrict litigation echo troubles articulated by men and women with whom we continue to speak on a weekly basis. These problems frequently involve heart attacks or cardiac arrest occurring inside hours following dialysis treatment options involving the administration of GranuFlo. The evidence emerging by way of discovery suggests that Fresenius may possibly have failed to act in a responsible style upon becoming conscious of this potential heart attack hyperlink a number of years ago.”

&#13

If you or somebody you know has suffered an injury that might be connected to GranuFlo, please get in touch with Audet &amp Partners, LLP by calling us toll cost-free at 800.965.1461. For extra data, you can visit our informational internet site at http://www.granuflodialysisrisk.com. &#13

&#13
U.S. District Court for the Southern District of Iowa, Case No. 3:2013cv00073

** United States Judicial Panel on Multidistrict Litigation, May 14, 2013 http://www.jpml.uscourts.gov/websites/jpml/files/Pending%20MDL%20Dockets_By%20District_Could-14-2013.pdf

&#13

*** New York Times, June 15, 2012 http://www.nytimes.com/2012/06/15/wellness/fda-investigates-fresenius-for-failure-to-warn-of-risk.html

&#13

**** FDA, May 25, 2012 http://www.fda.gov/Security/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm305630.htm

&#13
&#13
&#13
&#13
&#13

Far more Administrator Press Releases